MDxHealth (NASDAQ: MDXH) grants Joseph Sollee 237,100 share options

Rhea-AI Filing Summary

MDxHealth SA officer Joseph Sollee reported receiving two grants of share options as equity compensation. Each option allows him to purchase ordinary shares at an exercise price of $0.76 per share.

One grant covers 154,100 share options, which vest based on Company performance criteria evaluated by the Board at the end of specified performance periods. The second grant covers 83,000 share options, vesting in three equal annual installments on each of the first three anniversaries of the grant date. Both grants have an expiration date in 2036, providing long-term incentive tied to the Company’s results and his continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sollee Joseph

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Share Option	83,000	$0.00	--
Grant/Award	Share Option	154,100	$0.00	--

Holdings After Transaction: Share Option — 83,000 shares (Direct, null)

Footnotes (1)

1. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026. The options vest upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026 . The options vest in three equal installments on each of the first three anniversaries of the date of grant.

Key Figures

Option grant size: 154,100 share options Option grant size: 83,000 share options Exercise price: $0.76 per share +3 more

6 metrics

Option grant size 154,100 share options Performance-based grant to purchase ordinary shares

Option grant size 83,000 share options Time-based grant vesting over three years

Exercise price $0.76 per share Conversion price for both option grants

Expiration date May 28, 2036 Expiration for both share option grants

Performance-based vesting End of performance periods Vesting subject to Company performance criteria

Time-based vesting schedule 3 annual installments On each of the first three anniversaries of grant

Key Terms

Share Option, performance criteria, vesting, exercise price, +1 more

5 terms

Share Option financial

"Represents options to purchase ordinary shares at a price per share of $0.76"

performance criteria financial

"vest upon the achievement of certain Company performance criteria evaluated by the Board"

vesting financial

"The options vest in three equal installments on each of the first three anniversaries"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"options to purchase ordinary shares at a price per share of $0.76"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-05-28T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sollee Joseph

(Last) (First) (Middle)

CAP BUSINESS CENTER

ZONE INDUSTRIELLE DES HAUTS-SARTS

(Street)

HERSTAL BELGIUM 4040

(City) (State) (Zip)

BELGIUM

(Country)

2. Issuer Name and Ticker or Trading Symbol
MDxHealth SA [ MDXH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$0.76	06/01/2026		A		83,000		(1)	05/28/2036	Ordinary Shares	83,000	$0	83,000	D
Share Option	$0.76	06/01/2026		A		154,100		(2)	05/28/2036	Ordinary Shares	154,100	$0	154,100	D

Explanation of Responses:

1. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026. The options vest upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.

2. Represents options to purchase ordinary shares at a price per share of $0.76 granted on June 1, 2026 . The options vest in three equal installments on each of the first three anniversaries of the date of grant.

	/s/ Mark Busch, as attorney-in-fact for Joseph Sollee	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MDXH officer Joseph Sollee report on this Form 4?

Joseph Sollee reported receiving two grants of share options in MDxHealth SA. One grant covers 154,100 options and the other 83,000 options, both with an exercise price of $0.76 per share as part of his equity compensation.

How many MDXH share options were granted to Joseph Sollee and at what price?

Joseph Sollee received 154,100 share options in one grant and 83,000 in another. Each option allows purchase of MDxHealth SA ordinary shares at an exercise price of $0.76 per share under the company’s equity incentive arrangements.

What are the vesting conditions for Joseph Sollee’s MDXH performance-based options?

One grant of 154,100 options vests upon achievement of certain Company performance criteria. The Board of Directors evaluates these criteria at the end of the relevant performance periods, tying vesting directly to MDxHealth SA’s operational and strategic results.

How do the time-based MDXH options granted to Joseph Sollee vest?

The 83,000 MDxHealth SA share options vest in three equal installments. Vesting occurs on each of the first three anniversaries of the June 1, 2026 grant date, encouraging multi-year retention and alignment with long-term shareholder interests.

When do the MDXH share options granted to Joseph Sollee expire?

Both grants of share options to Joseph Sollee share the same expiration date. The options expire on May 28, 2036, giving him a long exercise window to potentially convert the options into ordinary shares if conditions and personal decisions align.

Are Joseph Sollee’s MDXH option grants open-market purchases or compensation awards?

The Form 4 describes both transactions as option grants or awards, not open-market purchases. They were issued at a $0.76 exercise price as equity compensation, classified under transaction code “A” for grant, award, or other acquisition by MDxHealth SA.